Brief: Biosynex FY Net Result Up At 1.1 Million Euros

Biosynex SA

06/04/2020 18:22

April 6 (Reuters) - BIOSYNEX SA  ALBIO.PA :
    * FY OPERATING RESULT EUR 1.3 MILLION VERSUS EUR 0.4 MILLION
YEAR
AGO
    * FY REVENUE EUR 34.2 MILLION VERSUS EUR 31.2 MILLION YEAR
AGO
    * WILL PROPOSE THREE NEW DIAGNOSTIC SOLUTUIONS FOR COVID-19
INFECTION
    * FY NET RESULT EUR 1.1 MILLION VERSUS EUR 0.5 MILLION YEAR
AGO
    * FY OPERATING RESULT EUR 1.3 MILLION VERSUS EUR 0.4 MILLION
YEAR
AGO
    * WILL CONTINUE ITS STRATEGY OF DEPLOYING ITS RAPID
DIAGNOSTIC
TEST SOLUTIONS IN 2020
    * COVID-19 DIAGNOSTICS SOLUTIONS INCLUDE TWO MOLECULAR
BIOLOGY
SOLUTIONS (PCR) AND ONE SEROLOGICAL TEST BIOSYNEX COVID-19 BSS
    * AT 31 DEC 2019, GROUP'S SHAREHOLDERS' EQUITY AMOUNTED TO €
30.4
MILLION, INCREASE OF € 1.1 MILLION COMPARED TO DEC 31, 2018
    * TO DATE, THE COMPANY HAS NOT HAD RECOURSE TO
STATE-GUARANTEED
LOANS OR DEFERRED PAYMENT OF ITS SOCIAL SECURITY AND TAX
CONTRIBUTIONS
    * GIVEN THE HIGH LEVEL OF ACTIVITY, RECOURSE TO SHORT-TIME
WORKING
WILL BE AN EXCEPTION
    * FY NET DEBT €7.2 MILLION VERSUS €3.0 MILLION YEAR AGO
    * INTENDS TO TAKE ADVANTAGE OF STRONG SYNERGIES LINKED TO
ACQUISITION OF VISIOMED GROUP'S FAMILY HEALTH DIVISION AND
DIVERSIFICATION OPPORTUNITIES ARISING FROM THE NEED FOR
CORONAVIRUS PREVENTION TO ACHIEVE STRONG GROWTH IN SALES IN 2020

Source text: https://bit.ly/34dsRaK
Further company coverage:  ALBIO.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))